Impact of combined MHT on breast cancer risk (incl Mirena ®)

Both estrogen postmenopausal therapy and estrogen-progestogen postmenopausal therapy are listed as ‘group one carcinogenic to human’ by the International Agency for Research on Cancer (American Cancer Society). The use of equine estrogen (CEE) combined with medroxy progesterone acetate (MPA) is associated with an increase in breast cancer. Using CEE-only entails a reduction of breast cancer r isk in the WHI-E study. Well-designed experimental studies indicate that some progestagens, including MPA, might interfere with apoptosis induced by estrogen.
Source: Maturitas - Category: Primary Care Authors: Tags: INV30 Source Type: research